GENEWIZ adds Cancer Panels to next generation sequencing service portfolio

Cancer Panels, which are available through Illumina and LifeTechnologies platforms, have the ability to screen and detect cancer causing genetic mutations from small amount of DNA.

Cancer Panels can accept samples extracted from formalin-fixed, paraffin-embedded (FFPE) thin sections as well as genomic DNA extracted from FFPE or non-FFPE, claims the company.

GENEWIZ next generation sequencing director Yankai Jia said NGS-based cancer panels allow for rapid analysis of multiple genes with faster turnaround time and lower cost compared to traditional methods such as Sanger DNA sequencing.

"The large amount of data generated is highly technical, so it’s important for researchers to have a trusted partner throughout the process who can provide the customized support and scientific expertise required," Jia added.